Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk Vitamin D for COVID-19  Alguwaihes et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 439 patients in Saudi Arabia Lower mortality with higher vitamin D levels (p=0.007) c19early.org Alguwaihes et al., Cardiovascular Diab.., Dec 2020 Favors vitamin D Favors control

Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study

Alguwaihes et al., Cardiovascular Diabetology, doi:10.1186/s12933-020-01184-4
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 439 diabetic hospitalized patients in Saudi Arabia showing lower mortality with vitamin D >12.5 nmol/L, adjusted hazard ratio aHR 0.14, p = 0.007.
This is the 31st of 192 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 611 vigintillion).
risk of death, 85.7% lower, RR 0.14, p = 0.007, high D levels 111, low D levels 328, inverted to make RR<1 favor high D levels, >12.5 nmol/L.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alguwaihes et al., 5 Dec 2020, retrospective, Saudi Arabia, peer-reviewed, 10 authors.
This PaperVitamin DAll
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study
Abdullah M Alguwaihes, Mohammed E Al-Sofiani, Maram Megdad, Sakhar S Albader, Mohammad H Alsari, Ali Alelayan, Saad H Alzahrani, Shaun Sabico, Nasser M Al-Daghri, Anwar A Jammah
Cardiovascular Diabetology, doi:10.1186/s12933-020-01184-4
Background: Information on the clinical characteristics and outcomes of hospitalized Covid-19 patients with or without diabetes mellitus (DM) is limited in the Arab region. This study aims to fill this gap.
Supplementary information Supplementary information accompanies this paper at https ://doi. org/10.1186/s1293 3-020-01184 -4. Additional file 1: Table S1 . Presenting symptoms and vital signs of Covid-19 patients according to severity and final outcome. S2 . Clinical characteristics of Covid-19 patients according to severity and outcome. S3 . Factors for outcomes of interest using the multivariate Cox proportional hazards regression model. Additional file 2: Table Additional file 3: Table Abbreviations Authors' contributions AMA, MEA and AAJ contributed to the study design and conducting the study. MM, SSA, MHA, AA, and SHA contributed to the data collection and conducting the study. SS wrote the manuscript and performed data analysis. AMA and NMA contributed to the data interpretation and fund acquisition. AMA is the guarantor of this work, has full access to the data and takes responsibility for the integrity of the data and accuracy of the data analysis. All authors critically reviewed and approved the manuscript in its original, revised and final form. All authors read and approved the final manuscript. Ethics approval and consent to participate Informed consent was waived by the Ethics Committee of the College of Medicine in King Saud University in Riyadh, Saudi Arabia (E-20-5090/July 5, 2020). Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher's Note Springer Nature remains..
References
Al-Daghri, Os, Alokail, Alkharfy, Yousef et al., Diabetes mellitus type 2 and other chronic noncommunicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic, BMC Med, doi:10.1186/1741-7015-9-76
Al-Daghri, Saleh, Aljohani, Vitamin D deficiency and cardiometabolic risks: a juxtaposition of Arab adolescents and adults, PLoS ONE, doi:10.1371/journal.pone.0131315
Alsofayan, Althunayyan, Khan, Hakawi, Assiri, Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study, J Infect Public Health, doi:10.1016/j.jiph.2020.05.026
Apicella, Campopiano, Mantuano, Mazoni, Coppelli et al., • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research ? Choose BMC and benefit from: reasons for worse outcomes, doi:10.1016/S2213-8587(20)30238-2
Caballero, Ceriello, Misra, Aschner, Mcdonnell et al., COVID-19 in people living with diabetes: an international consensus, J Diabetes Complications, doi:10.1016/j.jdiacomp.2020.107671
Ceriello, Standl, Catrinoiu, Itzhak, Lalic et al., Diabetes and Cardiovascular Disease (D&CVD)" Study Group of the European Association for the Study of Diabetes (EASD). Issues for the management of people with diabetes and COVID-19 in ICU, Cardiovasc Diabetol, doi:10.1186/s12933-020-01089-2
Coppola, Frojo, Chiumello, β-blockers in critically ill patients: from physiology to clinical evidence, Crit Care, doi:10.1186/s13054-015-0803-2
Docherty, Harrison, Green, Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ, doi:10.1136/bmj.m1985
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30120-1
Farsalinos, Barnouni, Poulas, Polosa, Caponnetto, Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis, Ther Adv Chronic Dis, doi:10.1177/2040622320935765
Galbadage, Peterson, Awada, Systematic review and meta-analysis of sex-specific COVID-19 clinical outcomes, Front Med, doi:10.3389/fmed.2020.00348
Habibi, Aroor, Das, Manrique-Acevedo, Johnson et al., The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat, Cardiovasc Diabetol
Hillson, COVID-19: diabetes and death. A call to action, Pract Diabetes, doi:10.1002/pdi.2271
Hussain, Baxi, Jamali, Nisar, Hussain, Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.08.014
Jin, Bai, He, Gender differences in patients with COVID-19: focus on severity and mortality, Front Public Health, doi:10.3389/fpubh.2020.00152
Lai, Lancet, Weiden, Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York City, JAMA Cardiol, doi:10.1001/jamacardio.2020.2488
Liu, Xie, Wang, Xiong, Chen et al., A comparative overview of COVID-19, MERS and SARS: review article, Int J Surg, doi:10.1016/j.ijsu.2020.07.032
Longo, Caruso, Maiorino, Bellastella, Giugliano et al., Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies, Cardiovasc Diabetol, doi:10.1186/s12933-020-01090-9
Maddaloni, Onofrio, Alessandri, Mignogna, Leto et al., Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II), Cardiovasc Diabetol, doi:10.1186/s12933-020-01140-2
Munshi, Hussein, Toraih, Elshazli, Vitamin D insufficiency as a potential culprit in critical Covid-19 patients, J Med Virol, doi:10.1002/jmv.26360
Ortona, Pierdominici, Rider, Editorial: sex hormones and gender differences in immune responses, Front Immunol, doi:10.3389/fimmu.2019.01076
Petrosillo, Viceconte, Ergonul, Ippolito, Petersen, COVID-19, SARS and MERS: are they closely related?, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.03.026
Reddy, Charles, Sklavounos, Dutt, Seed et al., The effect of smoking on COVID-19 severity: a systematic review and metaanalysis, J Med Virol, doi:10.1002/jmv.26389
Ren, Yang, Wang, Yan, Shi et al., Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19, Cardiovasc Diabetol, doi:10.1186/s12933-020-01035-2
Reynolds, Adhikari, Pulgarin, Troxel, Iturrate et al., Renin-angiotensinaldosterone system inhibitors and risk of Covid-19, N Engl J Med, doi:10.1056/NEJMoa2008975
Rezende, Thome, Schveitzer, Souza-Júnior, Szwarcwald, Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil, Rev Saude Publica, doi:10.11606/s1518-8787.2020054002596
Saavedra, Angiotensin receptor blockers and COVID-19, Pharmacol Res, doi:10.1016/j.phrs.2020.104832
Sardu, Gargiulo, Esposito, Paolisso, Marfella, Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19, Cardiovasc Diabetol, doi:10.1186/s12933-020-01047-y
Schnell, Standl, Catrinoiu, Itzhak, Lalic et al., Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group, Cardiovasc Diabetol
Shi, Zhang, Jiang, Zhang, Hu, Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center. Retrospective study, Diabetes Care, doi:10.2337/dc20-0598
Singh, Jain, Singh, Vitamin D deficiency in patients with diabetes and COVID-19 infection, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.06.071
Strope, Chau, Figg, Are sex discordant outcomes in COVID-19 related to sex hormones?, Semin Oncol, doi:10.1053/j.seminoncol.2020.06.002
Suleyman, Fadel, Malette, Clinical characteristics and morbidity associated with Coronavirus disease 2019 in a series of patients in metropolitan detroit, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.12270
Varikasuvu, Dutt, Thangappazham, Varshney, Diabetes and COVID-19: a pooled analysis related to disease severity and mortality, Prim Care Diabetes, doi:10.1016/j.pcd.2020.08.015
Varikasuvu, Varshney, Dutt, Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19, J Thromb Thrombolysis, doi:10.1007/s11239-020-02270-w
Weir, Thenappan, Bhargava, Chen, Does vitamin D deficiency increase the severity of COVID-19?, Clin Med, doi:10.7861/clinmed.2020-0301
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/nejmoa2001017
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit